Okomera specializes in automated 3D organoid screening technology that accelerates access to improved, precision-based cancer therapies. Their goal is to advance personalized medicine by providing healthcare actors with powerful tools to analyze how tumors respond to various therapies.
Okomera integrates standard assays on chip (eg. CRISPR, T-cell, cytotoxicity) to accelerate drug discovery from target to validation, and advance preclinical predictivity.
About the solution
They have developed a miniaturized 3D assay to help clinical decision. Using a biopsy of the tumor, Okomera’s cell culture technology includes: a fluidic machine, reagents, and a software analysis designed to estimate and identify the best drug treatment for each cancer patient.
Roowin is a privately owned Contract Research Organisation (CRO) headquartered in Riom (Auvergne), France. Its core business being in high value added fine chemistry, Roowin offers a large range of chemical services.
They support their customers and partners to advance their drug candidates from early research phase up to licensing out API in phase II or to the Market for small batches (about 20 kg).
About the solution
They are a french company specializing in high-value fine chemistry, is well-equipped to support biotech companies in need of GLP and GMP lots for toxicology studies and IND applications. With expertise in GMP synthesis and a focus on assisting customers from early research to later stages, Roowin is a potential partner for biotechs developing new clinical candidates.
BIOASTER is the first Institute for Technological Innovation in Microbiology in France (Lyon and Paris, Pasteur Institute). They are Non-for-profit Technology Research Institute, active in the field of vaccine, immunomodulation, microbiota, anti-infectives, and IVD. With BIOASTER, each project benefits from the right scientific and technology mix to address specific issues, quality in execution to meet high-standard requirements and case-by-case financial risk-sharing partnerships. Their industrial partners come from a wide range of industries, including pharma, biotech, animal health, nutrition and diagnostics.
About the solution
Examples of partnership themes include for vaccine : Memory response /Longitudinal study, Efficacy, Memory response /Longitudinal study,correlate of protection, Breadth of protection, benchmarking with competitives vaccines, vaccine & adjuvant MOA, Exploratory research, preclinical & clinical biomarkers identification, system serology, immunometabolism (immunophenotyping at single cell), microbiota & immunity, host pathogen interaction.
Examples of partnership themes include for bioprocess- bioproduction & CMC: biomarkers identification for batch success/batch failure, digital tween & machine learning/deep Learning, method development & benchmarking, antigen characterization, potency assays development, Host Cell Proteins identification, CMC methods for in vitro mRNA production, mRNA formulation.
SEQENS is a global partner in health, personal care and specialty ingredients. They empower innovation to bring the best solutions to our customers, with a constant concern for sustainability. Relying on the skills of 3300 employees, they leverage a worldwide manufacturing network, and state-of-the-art R&D centers. As an end-to-end player across the value chain, SEQENS offers a broad range of active ingredients, pharmaceutical intermediates, personal care & specialty ingredients. They innovate, develop and industrialize the most demanding molecules, and implement the best available technologies.
As a leading player of the health industry, SEQENS is committed to the therapies of the future and personalized medicine.
Driven by a culture of excellence and a strong entrepreneurial spirit, they share values such as unity, agility, and reactivity. They provide the highest level of service and quality to more than 1500 customers around the world while acting ethically in accordance to our strong CSR program.
About the solution
Streamline your development process with Seqens’ one-stop-shop CDMO services. They offer integrated support for all stages of your program, from discovery and preclinical studies to clinical development, market authorization, and even ongoing commercial manufacturing. This ensures seamless handoffs and reduces overall development timelines.
MaaT Pharma is the leading microbiome company in oncology. The Company owns in-house cGMP manufacturing capacities and specializes in developing Microbiome Ecosystem Therapies dedicated to enhancing the survival of cancer patients, with a focus on treating and preventing complications in blood cancers and improving treatments in immuno-oncology.
About the solution
MaaT013, a pooled-donor microbiome ecosystem therapy, is a non-immunosuppressive treatment dedicated to treat acute GvHD. As of today, MaaT013 has been administered to more than 200 patients. A Phase 3 trial is currently ongoing with ORR results expected in mid-2024. The Company has an open-IND granted by the U.S. FDA and has engaged active discussions with prominent US clinicians in the field of stem cell transplantation to explore the most efficient path forward to introduce MaaT013 to patients in the United States. MaaT013 has been awarded Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA).
MaaT033, a donor-derived, high-richness, high-diversity oral Microbiome Ecosystem TherapyTM containing is currently ongoing Phase 2 as an adjunctive therapy to improve overall survival in patients receiving HSCT and other cellular therapies. MaaT033 has been granted Orphan Drug Designation by the European Medicines Agency (EMA) in August 2023.
Cilcare is a biotech dedicated to harnessing auditory sciences to reshape the future of care via early diagnosis and targeted treatment. They believe hearing acts as a valuable indicator of our health and must be monitored and preserved accordingly. As awareness of the link between hearing and chronic health conditions grows, auditory sciences are paving the way for the early detection of chronic neurocognitive, inflammatory, and age-related diseases.
Founded in 2014 by three women with extensive backgrounds in the pharmaceutical industry, Cilcare initially aimed to address the significant unmet medical needs in ear diseases. Its approach focuses on translational research, supported by a cutting-edge R&D platform with robust pharmacological models. Partnering with CBSET, a translational institute linked to the MIT in 2017, Cilcare accelerated its mission, to drive transformative breakthroughs. Developing its own assets coupled with a unique AI-driven approach, Cilcare focuses on cochlear synaptopathy treatment and associated neuro-inflammatory disorders.
About the solution
Cilcare stands out with a revolutionary strategy that merges drug development with state-of-the-art AI-driven approach, specifically tailored for auditory data analysis. Cilcare’s lead compound, CIL001, is ready to enter phase IIA in the treatment of cochlear synaptopathy, a hot topic in the scientific community, and affecting 15% of the population. Addressing an underexplored therapeutic domain, with a unique pharmacological pathway, position Cilcare and its lead compound at the forefront of innovation in the field of auditory sciences.
OSE Immunotherapeutics is an integrated Clinical Stage biotech company mastering complex biology with regards to T-cells and myeloid cells, focused on developing first-in-class assets targeting immuno-oncology, Autoimmune and inflammatory diseases.
About the solution
OSE Immunotherapeutics has a dynamic partnership business model based on innovative products that generates non-dilutive revenues and finances R&D programs. These products have real blockbuster potential and give to OSE-Immunotherapeutics, an ability to conclude global agreements at different stages of their development with major pharmaceuticals players. We are interested to discuss potential collaborations. OSE-Immunotherapeutics actively seeks international partners for out-Licencing of compounds at all stages of clinical development of drug products.
Founded with the goal of revolutionizing precision medicine, Surge is an innovative company specializing in in-depth understanding of the immune system using AI. Thanks to significant technological advancements and a team of top-notch researchers coming from the US and from France, Surge is committed to creating innovative solutions to pave the way for personalized medicine of tomorrow. With the launch of its first product, PreCyte®, for predicting the risk of postoperative complications, and its premier laboratory, SurgeLab™, for acquiring individualized immune signatures, the company aims to become a leader in precision immune analysis.
About the solution
SurgeCare develops two main products : – SurgeLab™, a lab platform focused on acquiring immune signatures, and – PreCyte®, a range of medical devices for precision medicine.
Founded in 2021 with innovative technology for identifying predictive immune biomarkers, Surge, from 2021 to 2023, developed a first prototype to anticipate the risk of post-operative infections in patients undergoing major digestive surgery. A clinical study conducted from 2022 to 2023 revealed that their prototype outperforms existing methods by more than three times in terms of predictive capability. In 2024, this prototype enters its final phase of industrialization, with deployment planned as a pilot in the fourth quarter of 2024.
Meanwhile, in response to the growing interest of their partners, they have initiated the opening of their SurgeLab platform, which offers comprehensive immune screening, including ex-vivo blood stimulation, collection of biological parameters via a specialized panel, and data analysis through machine learning, reinforcing their commitment to innovation in precision medicine.
Neuron Experts is a private CRO, created in 2008, specialized in cultures of neurons mimicking neurodegenerative diseases. It is located in Marseille, France, where it has 250 m² of independent laboratory. 80% of its turnover is exported.
About the solution
Neuron Experts has developed its own tests based human and rat invitro models reproducing neurodegenerative diseases such as AD, PD, HD, ALS, MS diseases. These models allow to test efficacy of compounds from pharmaceutical and start-up as well as understanding their mode of action in theses pathologies
PK MED is a French innovative biotech company, privately owned and established in 2019 with the support of Truffle Capital, a prominent European Venture Capital firm specializing in Life sciences.
PK MED specializes in the innovative development of custom-designed, injectable, and biodegradable micro-implants. Their expertise spans across critical healthcare domains, focusing on local drug delivery systems for rheumatology (PKM-01) and enhancing cell-homing techniques to improve bone marrow transplantation outcomes (PKM-02).
About the solution
Lead product candidate PKM-01 is developed to treat gout, an excruciating and increasingly prevalent form of arthritis. Today, approved products take time to partially alleviate pain and come with real safety risks. PKM-01 is a drug combination product (sustained release formulation of the anti-inflammatory drug, colchicine, and an anesthetic) to be injected in the effected joint. PKM-01 is designed to be a new treatment paradigm in gout flares – a safe and very effective pain killer providing relief within minutes.
